City Therapeutics raised fresh funding through an upsized IPO to accelerate RNA interference development with a goal of pushing beyond liver-only delivery. The company’s lead RNAi program is positioned as an alternative approach to blockbuster-selling anticoagulants, supported by a platform that designs RNAi payloads and delivers them systemically to target tissues. The filing details cite prior partnerships in eye disease with Bausch + Lomb and CNS work with Biogen, reinforcing that delivery capability and target access remain central differentiators for next-generation RNAi companies. For the market, the move signals renewed capital appetite for modalities where delivery, not target biology, is the limiting step—and where scalable evidence can translate to registrational timelines.